Innovive licenses anthracycline prodrug

By Elaine Rigoli

Tampa, Fla., Aug. 22 - Innovive Pharmaceuticals, Inc. has licensed the patent rights from KTB Tumorforschungs GmbH, a free-standing research institute based in Freiburg, Germany, for the worldwide development and commercialization of DOXO-EMCH, a novel doxorubicin prodrug.

Innovive said it renamed the compound INNO-206 and plans to begin a phase 2 study in a solid tumor indication shortly.

INNO-206 is a prodrug of the commonly used chemotherapeutic doxorubicin. Once administered, INNO-206 binds circulating albumin via an acid sensitive linker. Circulating albumin is known to preferentially accumulate in tumors. Once in the acidic environment of the tumor, the albumin bound INNO-206, is cleaved to release free doxorubicin.

The company said a phase 1 study demonstrated safety and objective clinical responses in a variety of tumor types.

Innovive is a biopharmaceutical company based in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.